Literature DB >> 8375240

A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy.

M A Pfeifer1, D R Ross, J P Schrage, D A Gelber, M P Schumer, G M Crain, S J Markwell, S Jung.   

Abstract

OBJECTIVE: To investigate why, in spite of a vast variety of treatment agents, the alleviation of pain in patients with diabetic neuropathy is difficult. Previous studies have not used a treatment algorithm based on anatomic site and neuropathophysiological source of the neuropathic pain. RESEARCH DESIGN AND METHODS: A model that categorizes the types of pain into three groups (superficial, deep, and muscular) was applied in 75 diabetic patients with chronic (> 12 mo) painful distal symmetrical polyneuropathy in a controlled case series. Twenty-two patients were untreated and 53 patients were treated with imipramine +/- mexiletine for deep pain, capsaicin for superficial pain, and stretching exercises and metaxalone +/- piroxican for muscular pain. Each type of pain was scored separately on a scale of 0 (none) to 19 (worst), and the total of all three types was used as an index of overall pain. Ability to sleep through the night was scored by a scale of 1 (never) to 5 (always).
RESULTS: No significant differences were observed in initial pain scores, sleep scores, demographics, biochemistries, or physical findings between the two groups. After 3 mo a significant improvement in scores was noted in the treated but not the untreated patients. In addition, a significant difference was found in the change of scores between the treated and untreated patients: total pain (-18 +/- 2 vs. 0 +/- 2), deep pain (-7 +/- 1 vs. 0 +/- 1), superficial pain (-5 +/- 1 vs. 0 +/- 1), muscular pain (-6 +/- 1 vs. 0 +/- 1), and sleep (1.2 +/- 0.2 vs. 0.2 +/- 0.2), all P < 0.0001. In treated patients 21% became pain-free (total pain < 2), 66% had improvement (decrease in total pain > 5, but not total elimination of painful symptoms), and 13% were considered treatment failures (a decrease in total pain of < or = 5). This compares with 0 (P < 0.02), 10 (P < 0.0001), and 90% (P < 0.0001), respectively, in the untreated patients.
CONCLUSIONS: This study presents a new rationale and hypothesis for the successful treatment of chronic painful diabetic peripheral neuropathy. It uniquely bases the treatment algorithm on the types and sources of the pain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375240     DOI: 10.2337/diacare.16.8.1103

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

1.  Case report: patient's perspective on acute diabetic neuropathy.

Authors:  C S Kargel; M Godwin; D Alexander
Journal:  Can Fam Physician       Date:  2001-05       Impact factor: 3.275

Review 2.  Early diabetic neuropathy: triggers and mechanisms.

Authors:  Maxim Dobretsov; Dmitry Romanovsky; Joseph R Stimers
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 3.  Topical capsaicin for chronic neuropathic pain in adults.

Authors:  Sheena Derry; Rosalind Lloyd; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

4.  Pressure-induced pain: early sign of diabetes-associated impairment of insulin production in rats.

Authors:  Dmitry Romanovsky; Maxim Dobretsov
Journal:  Neurosci Lett       Date:  2010-08-01       Impact factor: 3.046

5.  Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial.

Authors:  Joachim F Wernicke; Joel Raskin; Amy Rosen; Yili L Pritchett; Deborah N D'Souza; Smriti Iyengar; Kelly Knopp; Trong K Le
Journal:  Curr Ther Res Clin Exp       Date:  2006-09

6.  Diabetic distal symmetric polyneuropathy: effect of low-intensity laser therapy.

Authors:  Mohammad Ebrahim Khamseh; Nooshafarin Kazemikho; Rokhsareh Aghili; Bijan Forough; Marjan Lajevardi; Fataneh Hashem Dabaghian; Ashrafeddin Goushegir; Mojtaba Malek
Journal:  Lasers Med Sci       Date:  2011-08-19       Impact factor: 3.161

7.  Comparison of the dissolution of metaxalone tablets (Skelaxin) using USP Apparatus 2 and 3.

Authors:  Janice Cacace; Eugene E Reilly; Anton Amann
Journal:  AAPS PharmSciTech       Date:  2004-02-06       Impact factor: 3.246

Review 8.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

9.  Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide.

Authors:  R R Wenzel; S Zbinden; G Noll; B Meier; T F Lüscher
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

10.  Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy.

Authors:  Hiroyuki Yamaoka; Hideyuki Sasaki; Hiroshi Yamasaki; Kenichi Ogawa; Takayuki Ohta; Hiroto Furuta; Masahiro Nishi; Kishio Nanjo
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.